|
注册号: Registration number: |
ChiCTR2500106425 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-23 16:00:06 |
|
注册时间: Date of Registration: |
2025-07-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
河北省脓毒症相关急性肾损伤的临床特征及影响因素:一项多中心横断面研究 |
|
Public title: |
Clinical characteristics and influencing factors of Sepsis-associated acute kidney injury in Hebei Province: a multicenter cross-sectional study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
河北省脓毒症相关急性肾损伤的临床特征及影响因素:一项多中心横断面研究 |
|
Scientific title: |
Clinical characteristics and influencing factors of Sepsis-associated acute kidney injury in Hebei Province: a multicenter cross-sectional study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵聪聪 |
研究负责人: |
胡振杰 |
|
Applicant: |
Cong-cong Zhao |
Study leader: |
Hu Zhenjie |
|
申请注册联系人电话: Applicant telephone: |
+86 135 8219 4511 |
研究负责人电话:
Study leader's |
+86 139 3385 6908 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
819273201@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
syicu@vip.sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北省石家庄市长安区健康路12号河北医科大学第四医院 |
研究负责人通讯地址: |
河北省石家庄市长安区健康路12号河北医科大学第四医院 |
|
Applicant address: |
No.12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, China. Hebei Medical University Fourth Hospital |
Study leader's address: |
No.12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, China. Hebei Medical University Fourth Hospital |
|
申请注册联系人邮政编码: Applicant postcode: |
050000 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
河北医科大学第四医院 |
||
|
Applicant's institution: |
The Fourth Hospital of Hebei Medical University |
||
|
研究负责人所在单位: |
河北医科大学第四医院 |
||
|
Affiliation of the Leader: |
The Fourth Hospital of Hebei Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025KS083 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河北医科大学第四医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Fourth Hospital of Hebei Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-02 00:00:00 | ||
|
伦理委员会联系人: |
贾会贤 |
||
|
Contact Name of the ethic committee: |
Jia Hui-xian |
||
|
伦理委员会联系地址: |
河北省石家庄市健康路 12 号 |
||
|
Contact Address of the ethic committee: |
12 Healthy Road, Shijiazhuang City, Hebei Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 158 8393 8160 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河北医科大学第四医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Fourth Hospital of Hebei Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省石家庄市长安区健康路12号河北医科大学第四医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, China. Hebei Medical University Fourth Hospital |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
暂无 |
||||||||||||||||||||||
|
Source(s) of funding: |
There is currently no funding source available |
||||||||||||||||||||||
|
研究疾病: |
脓毒症相关急性肾损伤 |
||||||||||||||||||||||
|
Target disease: |
Sepsis-associated acute kidney injury |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本研究联合多家省内三级医院ICU,旨在揭示河北省脓毒症相关急性肾损伤(SA-AKI)的流行病学特征及临床异质性,通过分析多中心SA-AKI患者临床指标,结合人口学、既往病史及治疗数据,明确河北省重症患者SA-AKI的预后及影响因素,为识别高危人群及改善患者预后提供数据支持。同时,纵向追踪患者预后,分析肾脏替代治疗模式及治疗剂量等干预措施对肾功能恢复率及病死率的影响,为优化SA-AKI分级诊疗和改善临床结局提供循证依据 |
||||||||||||||||||||||
|
Objectives of Study: |
This study, in collaboration with multiple provincial tertiary hospital ICUs, aims to reveal the epidemiological characteristics and clinical heterogeneity of sepsis associated acute kidney injury (SA-AKI) in Hebei Province. By analyzing clinical indicators of SA-AKI patients in multiple centers, combined with demographic, medical history, and treatment data, the prognosis and influencing factors of severe SA-AKI patients in Hebei Province are clarified, providing data support for identifying high-risk populations and improving patient prognosis. At the same time, longitudinal tracking of patient prognosis, analysis of the impact of intervention measures such as renal replacement therapy mode and treatment dose on renal function recovery rate and mortality rate, provide evidence-based basis for optimizing SA-AKI grading diagnosis and treatment and improving clinical outcomes |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、慢性肾脏病5期患者 2、接受过肾切除术的患者3、接受过肾脏移植的患者 4、血清肌酐峰值低于53 μmol/L的患者 5、血清肌酐变化无法归因于急性肾损伤的患者(例如因截肢导致的血清肌酐下降)6、接受规律透析的患者 7、入ICU24小时内放弃治疗或死亡患者 8、孕产妇及哺乳期妇女 9、电子病历无法获取的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with stage 5 chronic kidney disease, 2. Patients who have undergone nephrectomy, 3. Patients who have undergone kidney transplantation, 4. Patients with peak serum creatinine levels below 53 μ mol/L, 5. Patients whose serum creatinine changes cannot be attributed to acute kidney injury (such as a decrease in serum creatinine due to amputation), 6. Patients who receive regular dialysis, 7. Patients who give up treatment or die within 24 hours of ICU admission, 8. Pregnant and lactating women, 9. Patients whose electronic medical records cannot be obtained. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-01 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非RCT研究 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
not RCT study |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
联系通讯作者 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact the corresponding author |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF和Excel表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and Excel |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |